> Details

Thaweethai, Tanayott; Jolley, Sarah E.; Karlson, Elizabeth W.; Levitan, Emily B.; Levy, Bruce; McComsey, Grace A.; McCorkell, Lisa; Nadkarni, Girish N.; Parthasarathy, Sairam; Singh, Upinder; Walker, Tiffany A.; Selvaggi, Caitlin A.; Shinnick, Daniel J.; Schulte, Carolin C. M.; Atchley-Challenner, Rachel; Horwitz, Leora I.; Foulkes, Andrea S.; Aberg, Judith A.; Adolphi, Natalie L.; Ahirwar, Shreya; Ahmed, Shifa; Ahuja, Neera; Aikawa, Masanori; Akerlundh, Almary; [...]

Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection
  • Contributor: Thaweethai, Tanayott; Jolley, Sarah E.; Karlson, Elizabeth W.; Levitan, Emily B.; Levy, Bruce; McComsey, Grace A.; McCorkell, Lisa; Nadkarni, Girish N.; Parthasarathy, Sairam; Singh, Upinder; Walker, Tiffany A.; Selvaggi, Caitlin A.; Shinnick, Daniel J.; Schulte, Carolin C. M.; Atchley-Challenner, Rachel; Horwitz, Leora I.; Foulkes, Andrea S.; Aberg, Judith A.; Adolphi, Natalie L.; Ahirwar, Shreya; Ahmed, Shifa; Ahuja, Neera; Aikawa, Masanori; Akerlundh, Almary; [...]
  • Published: American Medical Association (AMA), 2023
  • Published in: JAMA, 329 (2023) 22, Seite 1934
  • Language: English
  • DOI: 10.1001/jama.2023.8823
  • ISSN: 0098-7484
  • Origination:
  • Footnote:
  • Description: ImportanceSARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals.ObjectiveTo develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections.Design, Setting, and ParticipantsProspective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling.ExposureSARS-CoV-2 infection.Main Outcomes and MeasuresPASC and 44 participant-reported symptoms (with severity thresholds).ResultsA total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months.Conclusions and RelevanceA definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.